Robeco Institutional Asset Management B.V. Sells 4,406 Shares of Quest Diagnostics Incorporated $DGX

Robeco Institutional Asset Management B.V. reduced its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 3.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 111,454 shares of the medical research company’s stock after selling 4,406 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.10% of Quest Diagnostics worth $21,241,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Perigon Wealth Management LLC lifted its stake in shares of Quest Diagnostics by 4.5% in the 3rd quarter. Perigon Wealth Management LLC now owns 1,275 shares of the medical research company’s stock valued at $243,000 after purchasing an additional 55 shares during the last quarter. True North Advisors LLC raised its holdings in Quest Diagnostics by 4.1% during the 3rd quarter. True North Advisors LLC now owns 1,554 shares of the medical research company’s stock valued at $296,000 after buying an additional 61 shares during the period. OLD Second National Bank of Aurora lifted its position in Quest Diagnostics by 14.9% in the third quarter. OLD Second National Bank of Aurora now owns 517 shares of the medical research company’s stock worth $99,000 after buying an additional 67 shares during the last quarter. World Investment Advisors boosted its stake in Quest Diagnostics by 2.7% during the second quarter. World Investment Advisors now owns 2,623 shares of the medical research company’s stock worth $471,000 after buying an additional 68 shares during the period. Finally, Harbor Capital Advisors Inc. increased its position in Quest Diagnostics by 0.6% during the second quarter. Harbor Capital Advisors Inc. now owns 10,789 shares of the medical research company’s stock valued at $1,938,000 after acquiring an additional 69 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO J. E. Davis sold 55,093 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total value of $10,589,976.46. Following the completion of the transaction, the chief executive officer directly owned 120,480 shares of the company’s stock, valued at approximately $23,158,665.60. The trade was a 31.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total value of $239,700.00. Following the sale, the director directly owned 17,037 shares in the company, valued at approximately $3,267,015.12. The trade was a 6.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 65,771 shares of company stock valued at $12,588,676. 8.16% of the stock is owned by insiders.

Quest Diagnostics Trading Down 0.2%

NYSE DGX opened at $177.76 on Friday. Quest Diagnostics Incorporated has a one year low of $148.70 and a one year high of $197.55. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. The company has a market capitalization of $19.77 billion, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 2.27 and a beta of 0.64. The company’s 50-day simple moving average is $181.30 and its two-hundred day simple moving average is $179.65.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.09. The firm had revenue of $2.82 billion during the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The company’s revenue was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.30 EPS. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics’s dividend payout ratio (DPR) is 37.56%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Barclays boosted their target price on Quest Diagnostics from $190.00 to $195.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 22nd. Evercore ISI increased their price target on Quest Diagnostics from $185.00 to $190.00 and gave the stock an “in-line” rating in a report on Wednesday, October 8th. UBS Group boosted their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the company a “neutral” rating in a report on Friday, October 17th. Finally, Mizuho increased their target price on Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Seven research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Quest Diagnostics currently has an average rating of “Hold” and an average target price of $197.27.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.